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Abstract
There is significant need to develop a single-dose rabies vaccine to replace the current multi-dose 
rabies vaccine regimen and eliminate the requirement for rabies immune globulin in post-exposure 
settings. To accomplish this goal, rabies virus (RABV)-based vaccines must rapidly activate B 
cells to secrete antibodies which neutralize pathogenic RABV before it enters the CNS. Increased 
understanding of how B cells effectively respond to RABV-based vaccines may improve efforts to 
simplify post-exposure prophylaxis (PEP) regimens. Several studies have successfully employed 
the TNF family cytokine a proliferation-inducing ligand (APRIL) as a vaccine adjuvant. APRIL 
binds to the receptors TACI and B cell maturation antigen (BCMA)–expressed by B cells in 
various stages of maturation–with high affinity. We discovered that RABV-infected primary 
murine B cells upregulate APRIL ex vivo. Cytokines present at the time of antigen exposure affect 
the outcome of vaccination by influencing T and B cell activation and GC formation. Therefore, 
we hypothesized that the presence of APRIL at the time of RABV-based vaccine antigen exposure 
would support the generation of protective antibodies against RABV glycoprotein (G). In an effort 
to improve the response to RABV vaccination, we constructed and characterized a live 
recombinant RABV-based vaccine vector which expresses murine APRIL (rRABV-APRIL). 
Immunogenicity testing in mice demonstrated that expressing APRIL from the RABV genome 
does not impact the primary antibody response against RABV G compared to RABV alone. In 
order to evaluate the necessity of APRIL for the response to rabies vaccination, we compared the 
responses of APRIL-deficient and wild-type mice to immunization with rRABV. APRIL 
deficiency does not affect the primary antibody response to vaccination. Furthermore, APRIL 
expression by the vaccine did not improve the generation of long-lived antibody-secreting plasma 
cells (PCs) as serum antibody levels were equivalent in response to rRABV-APRIL and the vector 
eight weeks after immunization. Moreover, APRIL is dispensable for the long-lived antibody-
secreting PC response to rRABV vaccination as anti-RABV G IgG levels were similar in APRIL-
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deficient and wild-type mice six months after vaccination. Mice lacking the APRIL receptor TACI 
demonstrated primary anti-RABV G antibody responses similar to wild-type mice following 
immunization with the vaccine vector indicating that this response is independent of TACI-
mediated signals. Collectively, our findings demonstrate that APRIL and associated TACI 
signaling is dispensable for the immune response to RABV-based vaccination.
Keywords
Rabies; Vaccine; APRIL; TACI; Antibody
1. Introduction
Despite known methods of effective RABV PEP, over 55,000 humans are killed by RABV 
annually; 99% of these deaths occur in resource-poor, canine-rabies endemic countries 
where control of the RABV reservoir is insufficient or nonexistent and access to medical 
care is limited (Hampson et al., 2015; WHO Publication, 2010). RABV PEP relies on 
RABV neutralizing antibodies (RVNAs) to confer protection by preventing the virus from 
reaching the CNS, causing clinical disease (Li et al., 2011; Schnell et al., 2010). Cell-culture 
based inactivated RABV vaccines currently used for RABV PEP are safe and effective but 
they have inherent problems (Shayam et al., 2006); multi-dose vaccination protocols and 
administration of costly rabies immunoglobulin at the initial clinical intervention are 
necessary because current vaccines fail to stimulate protective titers of RVNAs following the 
primary injection (Gacouin et al., 1999; Nagarajan et al., 2014; Wilde et al., 2002). 
Additionally, poor responders fail to mount protective responses even after repeated booster 
injections (Cabasso et al., 1974). Generating more immunogenic, protective vaccines against 
RABV would reduce the costs of prevention and save human lives (McGettigan, 2010). 
Increased understanding of how B cells effectively respond to RABV-based vaccines will 
guide the development of more effective, simplified PEP regimens.
In an effort to understand and potentially augment protective B cell responses to RABV-
based vaccines, we have evaluated the effects of the TNF family cytokine, APRIL, on the 
antibody response to RABV vaccination. APRIL is a TNF superfamily cytokine which is 
expressed by myeloid-derived cells including monocytes, macrophages, and dendritic cells. 
APRIL, like most TNF superfamily cytokines, forms soluble trimers which can bind to TNF 
receptors (reviewed in Mackay et al., 2003). APRIL trimers promiscuously bind to the TNF 
receptors transmembrane activator and calcium-modulator and cyclophilin ligand (CAML)-
interactor (TACI), and B cell maturation antigen (BCMA) (Yu et al., 2000). APRIL 
competes with its sister molecule, B-cell activating factor (BAFF), for receptor binding sites; 
APRIL and BAFF have diverse interactions, forming functional heterotrimers and regulating 
signaling through dynamic stoichiometric interactions with each other and receptors 
(Roschke et al., 2002; Schuepbach-Mallepell et al., 2015).
APRIL plays a role in lymphoid development and activation, influencing humoral immune 
responses; recombinant APRIL is a costimulator of B and T cells in vitro and leads to 
increased B cell numbers and T cell activation in vivo (Yu et al., 2000). APRIL transgenic 
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mice exhibit improved T-cell independent (TI) type 2 responses and demonstrate that APRIL 
boosts antigen-specific antiviral IgM responses to T-cell dependent (TD) antigens (Stein et 
al., 2002). Live RABV-based vaccine induces neutralizing IgM antibodies that are protective 
against pathogenic RABV challenge (Dorfmeier et al., 2013a); expression of APRIL in the 
context of RABV vaccination could improve this early protective response. Importantly, 
APRIL has also been shown to support antibody-secreting PC survival, suggesting that 
APRIL in the context of RABV vaccination might improve long-term antibody responses 
important in sustaining the protective effects of vaccination (Benson et al., 2008; Jourdan et 
al., 2014).
In this report, we evaluated the hypothesis that APRIL expression in temporospatial 
association with RABV antigen exposure during vaccination would augment and improve 
anti-RABV antibody responses. Interestingly, mice immunized with rRABV-mAPRIL 
demonstrated similar antibody responses to mice immunized with rRABV. In an effort to 
ascertain the role of APRIL in the response to RABV vaccination, we show that APRIL is 
dispensable for the anti-RABV G antibody response. Importantly, the antibody response to 
RABV vaccination does not depend on TACI-mediated signals. Collectively, our work 
provides new insight into the role of APRIL and TACI signaling in the context of antiviral 
responses. These results can guide future vaccine development, particularly those which rely 
on early antibody responses for protection.
2. Materials and Methods
2.1 In vitro splenocyte infection with rRABV and flow cytometry
Spleens were collected from 6–10 week old C57BL/6 mice (The Jackson Laboratory), 
homogenized, and red blood cells were lysed. Splenocytes were plated at 107 cells/mL, 
infected with rRABV at a multiplicity of infection (MOI) of 5 and cultured for 48 hours. 
Splenocytes were harvested, washed with FACS buffer (PBS containing 2% heat-inactivated 
FBS), blocked with anti-mouse CD16/32 antibody and surface stained with B220 (APC-
Cy7, RA3-6B2, BD Biosciences) and CD4 (APC, RM4.5, BD Biosciences). Cells were 
fixed in 2% paraformaldehyde and stained intracellularly using PermWash buffer (BD 
Biosciences) for RABV nucleoprotein (N) (FITC, Fujirebio Diagnostics, Inc.) and murine 
APRIL (PE, A3D8, Biolegend). Cells were resuspended in FACS buffer and analyzed on a 
BD LSR II flow cytometer. RABV N-positive gates were set so that mock-infected cells 
analyzed in parallel showed <1% RABV N-positive cells (Lytle et al., 2013; Norton et al., 
2014). Data were analyzed using FlowJo (FlowJo, LLC) and Prism 5 (Graphpad).
2.2 Recombinant RABV-based vaccine construction and recovery
rRABV is a molecular clone of the SAD-B19 vaccine strain of RABV (Conzelmann et al., 
1990; Schnell et al., 2000). To construct rRABV expressing APRIL, the murine APRIL gene 
was amplified from pCMV6-Kan/Neo-APRIL (OriGene, MC203367) by RT-PCR with Taq 
Polymerase (Invitrogen) using forward primer JPMRP-52 (5’- TTT CGT ACG ATT ATG 
CCA GCC TCA TCT CCA GG -3’) (BsiWI underlined) and reverse primer JPMRP-53 (5’- 
AAA GCT AGC TCA TAG TTT CAC AAA CCC CAG G -3’) (NheI underlined). Digestion 
and insertion of this PCR product into the rRABV plasmid using BsiWI and NheI (New 
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England Biolabs) resulted in recombinant RABV plasmid encoding murine APRIL. 
Infectious virus was recovered, concentrated and purified as described previously 
(McGettigan et al., 2001; Norton et al., 2014; Schnell et al., 2000) yielding rRABV-
mAPRIL.
2.3 One- and multi-step growth curves
Growth kinetics of rRABV and rRABV-mAPRIL were determined as previously described 
(McGettigan et al., 2003).
2.4 Western blotting
BSR cells were infected with rRABV or rRABV-APRIL at a MOI of 0.1. Cells lysates and 
100X concentrated virus-free supernatants were collected and SDS-PAGE separation was 
performed as previously described (Haley et al., 2017). Membranes were probed for one 
hour with anti-murine APRIL antibody (PE, A3D8, Biolegend) at a dilution of 1:500 in 
PBS-0.05% Tween 20 and scanned using a FluorChem M system (ProteinSimple).
2.5 In vitro splenocyte stimulation by rRABV-mAPRIL supernatant and flow cytometry
Splenocytes were collected as described in section 2.1 and cultured in 96-well flat-bottomed 
plates, 3×105 cells/well, for 72 hours in serial 3-fold dilutions of 100X concentrated 
supernatant from rRABV or rRABV-mAPRIL infected BSR cells, with a starting dilution of 
1:36 in RPMI-based splenocyte medium (Lytle et al., 2013; Norton et al., 2014). Cells were 
blocked and stained with LIVE/DEAD fixable AQUA (Invitrogen), B220/CD45R (APC-
Cy7, clone RA3-6B2, BD Biosciences) and CD4 (PE-CF594, clone GK1.5, BD 
Biosciences). Samples were fixed and analyzed on a BD LSR Fortessa flow cytometer. Data 
were analyzed using FlowJo (FlowJo, LLC.) and Prism 5 (Graphpad).
2.6 Evaluation of antibody responses to rRABV-mAPRIL
Groups of female 6–10 week old C57BL/6 mice (The Jackson Laboratory) were immunized 
intramuscularly (i.m.) with a single dose of 105 FFU of rRABV or rRABV-mAPRIL. On 
days 3, 5, 7, 10 and 56 post-immunization, blood was collected and serum was isolated for 
analysis. RABV G-specific IgG and IgM antibodies were determined by ELISA and 
reported at 1:50 serum dilution as described previously (Cenna et al., 2009, 2008; Dorfmeier 
et al., 2013b; Dunkel et al., 2015). VNA titers of pooled, heat-inactivated sera were 
determined using the RFFIT as described previously (Cenna et al., 2009, 2008).
2.7 Evaluation of antibody responses in APRIL-deficient mice
Groups of female 6–10 week old APRIL-deficient mice (B6.Cg-Tnfsf13tm1Pod/J, The 
Jackson Laboratory) (Xiao et al., 2008) or age-matched female C57BL/6 mice were 
immunized i.m. with a single dose of 105 FFU of rRABV. On days 3, 5, 7, 10, and 6 months 
post-immunization, blood was collected and serum was isolated for analysis. RABV G-
specific IgG and IgM, and VNA titers were determined as described in section 2.6.
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2.8 Evaluation of antibody responses in TACI-deficient mice
Groups of male 6–10 week old TACI-deficient mice (von Bülow et al., 2001) or age-
matched male C57BL/6 mice were immunized i.m. with a single dose of 105 FFU of 
rRABV. On days 7, 10, and 14 post-immunization, blood was collected and serum was 
isolated for analysis. RABV G-specific IgG antibody titers were determined as described in 
section 2.6.
3. Results
3.1 B cells upregulate APRIL expression following rRABV
To assess the potential of APRIL as an adjuvant for RABV vaccination, we evaluated the 
effect of live recombinant RABV-based vaccine (rRABV) treatment on primary murine B 
cell expression of APRIL ex vivo (Lytle et al., 2013). We isolated splenocytes from 
C57BL/6 mice, treated these cells with rRABV at a MOI of 5, allowed the cells to propagate 
in culture for 48 hours and then evaluated the intracellular expression of APRIL and RABV 
nucleoprotein (N) by flow cytometry (Figure 1A). The results demonstrate that rRABV-
infected murine B cells increase APRIL expression by 48 hours post-infection (Figure 1B). 
The upregulation of APRIL in response to rRABV suggests that APRIL signaling might 
play a role in effective B cell responses to the vaccine vector. Therefore, we hypothesized 
that temporospatial APRIL expression in association with RABV antigen exposure would 
improve the generation of protective antibodies against RABV glycoprotein (G) in response 
to RABV vaccination.
3.2 Construction, characterization and functional evaluation of a live, attenuated RABV-
based vaccine expressing murine APRIL
In order to test our hypothesis that the expression of APRIL will enhance RABV vaccine-
induced immunity, we constructed and recovered a recombinant, attenuated vaccine strain of 
RABV expressing murine april, rRABV-mAPRIL (Fig. 2A). The parental vector, rRABV, 
and rRABV-mAPRIL demonstrated similar growth kinetics (Figs. 2B and 2C), indicating 
insertion of this gene into the RABV genome does not affect the growth of RABV in vitro.
APRIL is unique among the TNF cytokines as it is cleaved intracellularly rather than at the 
cellular membrane. 30 kDa unprocessed APRIL is digested in the golgi by furin convertase 
yielding soluble 17 kDA monomers (López-Fraga et al., 2001). Western blot analysis of cell 
lysates from BSR cells infected with rRABV-mAPRIL or rRABV confirmed that rRABV-
mAPRIL, but not rRABV, expressed full-length APRIL, which was cleaved into soluble 
APRIL (Fig. 2D). Western blot analysis of supernatants from rRABV-mAPRIL-infected 
BSR cells demonstrated the presence of soluble APRIL monomers. The results confirm that 
rRABV-mAPRIL expresses full-length APRIL which is processed into secreted monomers.
To ensure virally encoded, secreted APRIL was functional, primary murine splenocytes were 
cultured with serial dilutions of purified and concentrated supernatants from BSR cell 
cultures infected with rRABV or rRABV-mAPRIL. After 72 hours, splenocytes were 
harvested, stained with Live/Dead Aqua, α-B220 APC-Cy7, and α-CD4 PE, then analyzed 
by flow cytometry (Fig. 2E). Exposure of splenocytes to virus-free supernatant from 
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rRABV-mAPRIL-infected cells significantly increased the percentage of live B cells 
compared to supernatant from rRABV-infected cells (Fig. 2F), indicating that APRIL 
secreted by rRABV-mAPRIL infected cells is functional.
3.3 APRIL expression in association with RABV antigen exposure does not modulate the 
primary antibody response to RABV vaccination
To evaluate the effect of APRIL expression in association with RABV antigen on the 
immunogenicity of rabies vaccination, mice were immunized i.m. with 105 FFU rRABV or 
rRABV-mAPRIL. The kinetics of the primary immune response to vaccination were 
monitored by serum levels of total anti-RABV G IgM and IgG antibodies at various times 
post-immunization. rRABV-mAPRIL induced levels of anti-RABV G IgM (Fig. 3A) and 
IgG (Fig. 3B) comparable to mice immunized with rRABV at all times evaluated. Consistent 
with the antibody levels determined by ELISA, RVNA titers in mice immunized with 
rRABV-mAPRIL or rRABV were similar at all times (Fig 3C). RVNAs reached levels 
indicative of a satisfactory immunization (greater than 0.5 IU/mL) (“CDC - Doctors: Rabies 
Serology - Rabies,” n.d.) by day 7 post-immunization in response to rRABV and rRABV-
mAPRIL.
3.4 APRIL is dispensable for the primary antibody response to RABV vaccination
While APRIL expression in the context of rRABV-mAPRIL did not alter the 
immunogenicity of rRABV, APRIL’s influence on the immune response to RABV 
vaccination had yet to be evaluated. We employed an APRIL-deficient mouse model to 
characterize the role of APRIL in the primary anti-RABV G antibody response to 
vaccination. Mice devoid of APRIL (Xiao et al., 2008) or control (C57BL/6) mice were 
immunized i.m. with a single dose of 105 FFU rRABV. The kinetics of the primary immune 
response to vaccination were evaluated by serum levels of total anti-RABV G IgM and IgG 
antibodies at various times post-immunization. At all times evaluated the anti-RABV G IgM 
(Fig. 4A) and IgG (Fig. 4B) antibody levels were equivalent between the APRIL-deficient 
and C57BL/6 mice. RVNA titers were correspondingly similar between C57BL6 and 
APRIL-deficient mice at all times. These results demonstrate that APRIL is dispensable for 
the primary antibody response to RABV vaccination.
3.5 APRIL does not influence long-lived antibody responses to RABV vaccination
APRIL has been documented to support the survival of antigen-specific PCs (O’Connor et 
al., 2004). In order to evaluate whether APRIL expression associated with RABV antigen 
exposure influenced long-lived antibody responses, serum IgG levels in C57BL/6 mice 
immunized i.m. with 105 FFU rRABV or rRABV-mAPRIL were compared 8 weeks post-
immunization. The levels of anti-RABV G IgG at this time were similar between rRABV 
and rRABV-mAPRIL immunized mice (Fig. 5A).
In an effort to determine whether APRIL was necessary to support long-lived antibody 
responses to RABV vaccination, serum IgG levels 6 months after immunization were 
compared between C57BL/6 mice and APRIL-deficient mice immunized i.m. with 105 FFU 
rRABV. Sustained antibody responses were similar between APRIL-deficient and control 
mice indicating that APRIL is dispensable for long-lived anti-RABV antibody responses 
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(Fig. 5B). This is in agreement with previous work which indicates BAFF can signal through 
BCMA to support PC survival in vivo (Benson et al., 2008). Taken together, neither APRIL 
expression at the time of antigen exposure nor APRIL deficiency modulates the long-lived 
antibody-secreting PC response to RABV vaccination.
3.6 The primary antibody response to RABV vaccination is independent of TACI signaling
APRIL binds to TACI and BCMA which are differentially expressed by B cells. Previous 
studies have demonstrated that BCMA deficiency or transgenic expression does not affect B 
cell development or antigen-specific B cell responses (Schneider et al., 2001; Xu and Lam, 
2001). In contrast, TACI-deficient and soluble TACI transgenic mice have demonstrated 
significant roles for TACI in the regulation of humoral immune responses (Zhang et al., 
2015). In order to confirm that the highest affinity APRIL receptor, TACI, is not required for 
the primary antibody response to RABV vaccination, TACI-deficient mice were immunized 
i.m. with a single dose of 105 FFU rRABV. Serum levels of total anti-RABV G IgG 
antibodies were evaluated at various times post-immunization (Fig. 6). TACI-deficiency did 
not affect the primary antibody response to RABV vaccination indicating that this response 
is independent of TACI signaling.
4. Discussion
Neutralization of APRIL and BAFF by TACI-Fc and BCMA-Fc fusion proteins has been 
shown to diminish antibody responses against the TD antigens, suggesting that this signaling 
system might be important for the TD response to rRABV (Haley et al., 2017; Xia et al., 
2000; Yu et al., 2000). Increased expression of APRIL in RABV-infected primary murine B 
cells suggested that APRIL expression in the context of RABV-based vaccines could 
augment immunogenicity. Indeed, previous HIV vaccine studies have successfully employed 
APRIL as an adjuvant (Gupta et al., 2015; Kanagavelu et al., 2012; Melchers et al., 2012).
Surprisingly, rRABV-mAPRIL did not elicit more robust anti-RABV antibody responses 
compared to rRABV. This could be a direct consequence of the systemic immunity needed 
for effective protection against RABV. APRIL has been a successful adjuvant in vaccines 
targeting HIV which require strong mucosal immunity since the gut is the major site of HIV 
replication (Brenchley and Douek, 2008). However, APRIL plays significantly different 
roles in mucosal and systemic immunity. APRIL secreted by gut endothelium, eosinophils 
and dendritic cells supports class-switching towards IgA and thereafter maintains IgA+ PCs 
in the intestinal lamina propria (Barone et al., 2009; Chu et al., 2011; He et al., 2007). While 
IgA responses are critical for mucosal immunity, the systemic response to RABV required 
for protection depends on IgG and IgM (Dorfmeier et al., 2013a). Lack of heparin sulfate 
proteoglycans (HSPGs) in the microenvironment in which APRIL is expressed by rRABV-
mAPRIL may also underlie rRABV-mAPRIL’s lack of effect on the anti-RABV antibody 
response. APRIL cross-linking on HSPGs optimizes APRIL signaling through TACI, the 
only APRIL receptor involved in early humoral responses (Bossen et al., 2008; Xu and Lam, 
2001). If APRIL is unable to cross-link on HSPGs in the context of the response to rRABV 
then exogenous and endogenous APRIL would likely be irrelevant in the anti-RABV 
response.
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Our results in APRIL-deficient mice confirm that the anti-RABV antibody response to 
vaccination does not depend on endogenous APRIL. Th1 responses have been associated 
with strong antibody responses to RABV vaccination (Cenna et al., 2009). Previous findings 
document intact Th1 immune responses in APRIL-deficient mice (Stein et al., 2002), likely 
enabling the equivalent responses to RABV vaccination in APRIL-deficient and wild-type 
mice. It is possible that BAFF outcompetes APRIL for TACI binding sites as BAFF has a 
higher affinity for TACI than does APRIL (Hymowitz et al., 2005). This scenario is 
plausible given the intact responses to rRABV immunization in APRIL-deficient mice.
Confirmatory studies in TACI-deficient mice demonstrated comparable antibody responses 
to control mice against rRABV. Since TACI is the highest affinity APRIL receptor and the 
only APRIL receptor documented to play a role in early humoral responses, this finding 
reiterates that APRIL is inconsequential in the anti-RABV response. Our finding agrees with 
previous reports that TACI-deficient mice have intact in vivo antibody responses to TD 
antigens (von Bülow et al., 2001; Yan et al., 2001).
Collectively, our results demonstrate that the APRIL:TACI signaling axis is not required for 
effective RABV vaccination. APRIL expression in temporospatial association with RABV 
antigen exposure does not improve the anti-RABV antibody response to vaccination. Indeed, 
we have demonstrated that neither APRIL nor TACI signaling are required for the antibody 
response to RABV vaccination. Our work provides new insight into the role of APRIL and 
TACI signaling in the context of antiviral responses. Specifically, the APRIL-TACI signaling 
axis is unlikely to be successfully manipulated for RABV vaccine development.
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Glossary
APRIL a proliferation inducing ligand
BAFF B cell activating factor
BAFFR BAFF receptor
BCMA B cell maturation antigen
CAM calcium-modulator and cyclophilin ligand
HSPG heparan sulfate proteoglycans
G glycoprotein
GC germinal center
PC plasma cell
PEP post-exposure prophylaxis
RABV rabies virus
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rRABV recombinant SAD-B19 rabies vaccine
rRABV-mAPRIL recombinant rabies vaccine expressing murine APRIL
RVNA rabies virus neutralizing antibodies
TACI T cell activator and CAML inhibitor
TD T cell dependent
TI T cell independent
TNF tumour necrosis family
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Highlights
• Like BAFF, APRIL is a TNF family cytokine that plays critical roles in B cell 
responses.
• Unlike BAFF, little is known about the role of APRIL in vaccine-induced 
immunity against viral infections.
• A recombinant rabies vaccine expressing murine APRIL does not modulate 
the immunogenicity of the vector.
• The APRIL:TACI axis is dispensable for the primary and secondary immune 
response to a recombinant rabies vaccine.
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Figure 1. 
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Figure 2. 
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Figure 3. 
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Figure 4. 
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Figure 5. 
Haley et al. Page 18
Antiviral Res. Author manuscript; available in PMC 2018 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 6. 
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